August 30, 2024 02:09 PM EDT
Pharma

No­vo Nordisk re­veals post-hoc car­dio­vas­cu­lar da­ta for semaglu­tide

Nicole DeFeudis

Editor

No­vo Nordisk bol­stered its heart dis­ease da­ta for semaglu­tide on Fri­day with ad­di­tion­al analy­ses from a hand­ful of tri­als.

In a pooled analy­sis of cer­tain …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

GSK, iTeos re­ju­ve­nate strug­gling TIG­IT space with pos­i­tive Phase 2 Jem­per­li com­bo da­ta in lung can­cer

#ES­MO24 roundup: New da­ta on Am­gen’s PRMT5 in­hibitor seem lack­lus­ter, and Jazz’s HER2 an­ti­body

Ad­comm says In­ter­cep­t's rare liv­er dis­ease drug should not get full ap­proval

A service from the Financial Times